Please assess the completion status of the following clinical trial:

Trial Title: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant had a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis)~* Participants with moderate to severe RA defined as a Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 C-Reactive Protein (CRP) score \>3.2~* Biologically treatment naïve and initiated adalimumab at baseline visit, as per standard daily clinical practice~* Availability of clinical data of the previous 12 weeks prior to baseline~* Ability to self-complete participant questionnaires.~* Participants had signed the authorization (or informed consent where applicable) to disclose and use personal health information after having been prescribed adalimumab~Exclusion Criteria:~* Participants who were pregnant or breastfeeding at enrollment or wished to become pregnant in the next 24 weeks.~* Participation in any RA-related clinical trial at the time of enrollment, at baseline, or at any point during the past 24 weeks prior to baseline~* Participants, who in the clinician's view, may not have been able to accurately report their quality of life (QoL) or prior resource utilization~* Participants, who in the clinician's view, may not have been able to adhere to adalimumab therapy over 24 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with RA receiving adalimumab (Type: None): 40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).